The PI3K/AKT/mTOR signaling pathway, critically involved in tumor growth, proliferation, metabolism, and migration, represents one of the most frequently dysregulated pathways in breast cancer therapeutics (Liu et al., 2024). This evidence concerns the gene MTOR and breast carcinoma.